Proposed Mechanism of Action
NA
Additional Detail
NA
Proposed Mechanism of Action
SERD (ER)
Additional Detail
ELCIN Trial is an open-label multicenter Ph 2 trials of Elacestrant in women and men with CDK4/6 inhibitor naïve ER+/HER2- metastatic breast cancer. The study investigates elacestrant as single agent without prior CDK4/6i exposure.
Proposed Mechanism of Action
SERD (ER)
Additional Detail
ELECTRA Trial is An Open-label Multicenter Phase 1b/2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor positive, HER-2 Negative Breast Cancer. ELECTRA is a Global Study with the aim of determining the activity of elacestrant in combination with Abemaciclib in BC EH+/HER2- with brain metastases.
Proposed Mechanism of Action
SERD (ER)
Additional Detail
ELEVATE Trial is A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in various combination in patients with ER+/HER2- metastatic Breast Cancer. ELEVATE is a Global Study which the aim of determining safety and efficacy of combining elacestrant with other agents in the metastatic setting.
Proposed Mechanism of Action
Targeted Biologic (CD123)
Additional Detail
TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor a (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. TAGRAXOFUSP was approved by the U.S. FDA in 2018 for the treatment of adult and pediatric patients, 2 years or older, with BPDCN.
Indication
BPDCN
Proposed Mechanism of Action
Targeted Biologic (CD123)
Additional Detail
ELZONRIS was approved by the EMA in 2021 as monotherapy for the first-line treatment of adult patients with BPDCN.
Miami Breast Cancer Conference® (MBCC)
Posters
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
Product: Orserdu
Bardia A, Neven P, Montero AJ, et al
Miami Breast Cancer Conference® (MBCC) March 2022
Poster
American Association for Cancer Research® (AACR)
Posters
Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: A translational investigation
Product: Orserdu
Dubash TD, Bardia A, Chirn B, et al
American Association for Cancer Research® (AACR) April 2023
Poster CT073
The oral SERD elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models
Product: Orserdu
Merlino G, Fiascarelli A, Talucci S, et al
American Association for Cancer Research® (AACR) April 2023
Poster 2849
Assistance
Chat
Looking for more information?
-
Contact Stemline Therapeutics US
Medical Information -
Submit Medical Inquiry -
Schedule a Virtual Meeting
Report an Adverse Event/
Product Quality Complaint
Linkedln
Pipeline and Clinical Trials
At Stemline Therapeutics, we are committed to applying our scientific leadership to transform the lives of people with cancer. We are focused on the development of a broad pipeline of innovative, transformative therapies in oncology.
Stemline Pipeline
Clinical Trials
Hematology
Tagraxofusp | Anti-CD123
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
Monotherapy 1L and relapsed/refractory BPDCN |
STML-401-0114 NCT02113982 |
|
|
Monotherapy R/R AML |
NCT02113982 | |
|
+ Venetoclax + azacitidine 1L unfit CD123+ AML |
TRILLIUM NCT06456463 |
|
|
Monotherapy High-risk 1L or R/R CMML or R/R MF |
NCT02268253 | |
Dapolsertib | PIM/FLT3 inhibitor
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
+ Glofitamab R/R DLBCL |
JASPIS-01 NCT06534437 e |
Tagraxofusp | Anti-CD123
REGIMEN | PATIENT POPULATION
Monotherapy | 1L and relapsed/refractory BPDCN
TRIAL
STML-401-0114
NCT02113982
PHASE
REGIMEN | PATIENT POPULATION
Monotherapy | R/R AML
TRIAL
NCT02113982
PHASE
REGIMEN | PATIENT POPULATION
+ Venetoclax + azacitidine | 1L unfit CD123+ AML
TRIAL
TRILLIUM
NCT06456463
PHASE
REGIMEN | PATIENT POPULATION
Monotherapy | High-risk 1L or R/R CMML or R/R MF
TRIAL
NCT02268253
PHASE
Dapolsertib | PIM/FLT3 inhibitor
REGIMEN | PATIENT POPULATION
+ Glofitamab | R/R DLBCL
TRIAL
JASPIS-01 | NCT06534437e
PHASE
Solid Tumors
Elacestrant | SERD
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
Monotherapy ER+/HER2− aBC ESR1-mut |
EMERALDa NCT03778931 |
|
|
Monotherapy ER+/HER2- eBC with high risk of recurrence |
ELEGANT NCT06492616 |
|
|
+ Everolimus ER+/HER2-, ESR1-mut aBC |
ADELA* NCT06382948b *This is a global study with no US trial sites. |
|
|
+ Abemaciclib, ribociclib, palbociclib, everolimus, capivasertib, or alpelisib ER+/HER2- mBC |
ELEVATE NCT05563220 |
|
|
+ Abemaciclib ER+/HER2- mBC with brain metastases |
ELECTRA NCT05386108 |
|
|
Monotherapy CDK4/6i-naive ER+/HER2- mBC |
ELCIN NCT05596409 |
|
|
+ Samuraciclib ER+/HER2- locally a/mBC |
SUMIT-ELA NCT05963997c |
MEN2312 | KAT6 inhibitor
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
| Mono- and combination therapy | MEN2312-01 NCT06638307 |
SL-701 | IL-13Ra2, EphA2, survivin
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
+ Bevacizumab Recurrent glioblastoma multiforme |
NCT02078648 |
MEN1309 | Anti-CD205 ADC
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
Monotherapy CD205+ recurrent or metastatic solid tumors |
NCT04064359d |
MEN2501 | KIF18A inhibitor
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
Mono- and combination therapy |
MEN2501-01 NCT07226427 |
MEN2602 | Biologic
|
REGIMEN PATIENT POPULATION |
TRIAL | PHASE |
|---|---|---|
|
Monotherapy |
Solid Tumors
Elacestrant | SERD
REGIMEN | PATIENT POPULATION
Monotherapy | ER+/HER2− aBC ESR1-mut
TRIAL
EMERALDa | NCT03778931
PHASE
REGIMEN | PATIENT POPULATION
Monotherapy | ER+/HER2- eBC with high risk of recurrence
TRIAL
ELEGANT | NCT06492616
PHASE
REGIMEN | PATIENT POPULATION
+ Everolimus | ER+/HER2-, ESR1-mut aBC
TRIAL
ADELA* | NCT06382948b
*This is a global study with no US trial sites.
PHASE
REGIMEN | PATIENT POPULATION
+ Abemaciclib, ribociclib, palbociclib, everolimus, capivasertib, or alpelisib | ER+/HER2- mBC
TRIAL
ELEVATE | NCT05563220
PHASE
REGIMEN | PATIENT POPULATION
+ Abemaciclib | ER+/HER2- mBC with brain metastases
TRIAL
ELECTRA | NCT05386108
PHASE
REGIMEN | PATIENT POPULATION
Monotherapy | CDK4/6i-naive ER+/HER2- mBC
TRIAL
ELCIN | NCT05596409
PHASE
REGIMEN | PATIENT POPULATION
+ Samuraciclib | ER+/HER2- locally a/mBC
TRIAL
SUMIT-ELA | NCT05963997c
PHASE
MEN2312 | KAT6 inhibitor
REGIMEN | PATIENT POPULATION
? Elacestrant | ER+/HER2- a/mBC
TRIAL
MEN2312-01
NCT06638307
PHASE
SL-701 | IL-13Ra2, EphA2, survivin
REGIMEN | PATIENT POPULATION
+ Bevacizumab | Recurrent glioblastoma multiforme
TRIAL
NCT02078648
PHASE
MEN1309 | Anti-CD205 ADC
REGIMEN | PATIENT POPULATION
Monotherapy | CD205+ recurrent or metastatic solid tumors
TRIAL
NCT04064359d
PHASE
MEN2501 | KIF18A inhibitor
REGIMEN | PATIENT POPULATION
Mono- and combination therapy
TRAIL
MEN2501-01
NCT07226427
PHASE
MEN2602 | Biologic
REGIMEN | PATIENT POPULATION
Monotherapy
TRIAL
PHASE
REGIMEN | PATIENT POPULATION
Monotherapy | Advanced solid tumors
TRIAL
NCT02667873
PHASE
The information in the table reflects the development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products have not been established and marketing approval has yet to be granted by regulatory authorities.
1L: first-line; ADC: antibody drug conjugate; aBC: advanced breast cancer; AML: acute myeloid leukemia; BPDCN: blastic plasmacytoid dendritic-cell neoplasm; CD123: interleukin-3 receptor; CDK4/6i: cyclin-dependent kinase 4/6 inhibitor; CMML: chronic myelomonocytic leukemia; DLBCL: diffuse large B-cell lymphoma; eBC: early breast cancer; EphA2: ephrin receptor A2; ER+: estrogen receptor-positive; ESR1: estrogen receptor 1; ET: endocrine therapy; FLT3: fms-like tyrosine kinase 3; HER2-: human epidermal growth factor receptor 2-negative; HR+: hormone receptor-positive; IL-13Ra2: interleukin-13 receptor subunit alpha 2; IND: Investigational new drug; KAT6i: K (lysine) acetyltransferase 6; KIF18A: kinesin family member 18A; MF: myelofibrosis; MOA: mechanism of action; mut: mutant; PARPi: poly-ADP ribose polymerase inhibitor; PIM: proviral integration site for Moloney murine leukemia virus; R/R: relapsed or refractory; SERD: selective estrogen receptor degrader.
aOrserdu. Prescribing information. Stemline Therapeutics, Inc. 2026; bClinical trial collaboration with MEDSIR; cClinical trial collaboration with Carrick Therapeutics; dClinical development partnered with Oxford BioTherapeutics; eRyvu Therapeutics S.A. sponsored study.
Find a Trial
To get started, select disease state, condition and the product below
- Summary & Overview
- Key Eligibility Criteria
- Treatment(s) Being Studied
- Trial Site Locations
- Clinical Trial Overview
Summary
Phase 2, Phase 1
(Adult,? Older Adult)
Enrollment ()
Study type
Location
Study Start
Primary Completion
Study Completion
Overview
For drug specific questions, click here
View locations for this study
Find the closest locations, your results will be shown below
This study has locations
View locations for this study
Find the closest location, your results will be shown below
This study has locations
Clinical Trial Cards
Elacestrant in women and men with CDK4/6 inhibitor-naive ER+/HER2- metastatic breast cancer: An open-label multicenter Phase 2 study
Valid Till: 15-10-2026
An open-label multicenter Phase 1b/2 study of elacestrant in combination with abemaciclib in women and men with brain metastasis from ER+/HER2- breast cancer
Valid Till: 15-10-2026
A Phase 3 study of elacestrant ± everolimus in patients with ESR1-mut ER+/HER2? mBC who progressed on prior ET + CDK4/6i
Valid Till: 21-11-2026
A randomized Phase 3 study of elacestrant vs standard ET in patients with ER+/HER2- eBC with a high risk of recurrence
Valid Till: 11-10-2026
Phase III ELEGANT Study Design Summary
Valid Till: 25-02-2027
TRILLIUM Study: Triplet Therapy in AML Clinical Trial Overview Card.May 2025
Valid Till: 12-05-2027
A Phase 1b/2, open-label umbrella study to evaluate safety and efficacy of elacestrant in various combinations in patients with metastatic breast cancer
Valid Till: 15-10-2026
A Phase 1b/2 open-label study of samuraciclib in combination with elacestrant in participants with metastatic or locally advanced HR+/HER2- breast cancer
Valid Till: 18-10-2026
Report an Adverse Event/ Product Quality Complaint
Stemline Therapeutics prioritizes patient safety. Please use one of the following methods to report adverse events or product complaints.
To report, call 1-877-332-7961 or click here.